Skip to content

Study · Non-randomized trial · n = 5 · 2005

2 results

Insulin-like factor 3 serum levels in 135 normal men and 85 men with testicular disorders: relationship to the luteinizing hormone-testosterone axis.

Bay K, Hartung S, Ivell R, Schumacher M, Jürgensen D, Jorgensen N, Holm M, Skakkebaek NE, Andersson AM

The Journal of clinical endocrinology and metabolism8 Mar 2005Cited by 139 (Europe PMC)

PMID15755855 (opens in a new tab)DOI10.1210/jc.2004-2257 (opens in a new tab)PepBankPUB-15755855
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In unilaterally orchiectomized former testis cancer patients, INSL3 remained unchanged 72 and 96 h after hCG stimulation.

    In plain wordsIn former testis cancer patients with one testis removed, hCG stimulation did not change blood INSL3 levels.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    No significant changeINSL3 after hCG stimulation
    Study

    n = 2

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In two unilaterally orchiectomized former testis cancer patients, who underwent hCG stimulation test, INSL3 serum levels were unchanged 72 and 96 h after hCG stimulation.
  2. 02HumanObservational studyEfficacy outcome

    In men with hypogonadotropic hypogonadism receiving hCG, median serum INSL3 was 0.36 ng/ml, with percentiles 0.13-0.73 ng/ml.

    In plain wordsIn men with hypogonadotropic hypogonadism receiving hCG, median INSL3 in blood was 0.36 ng/ml.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    Not applicableSerum INSL3 during hCG treatment
    Study

    n = 5

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median serum INSL3
    0.36 ng/ml
    Hypogonadotropic hypogonadism with hCG treatment
    2.5th-97.5th percentile range of serum INSL3
    0.13 to 0.73 ng/ml
    Hypogonadotropic hypogonadism with hCG treatment

    Source sentences

    Summary
    and men with hypogonadotropic hypogonadism and human chorionic gonadotropin (hCG) treatment (n = 5), 0.36 (0.13-0.73) ng/ml.
    Summary
    Median (2.5-97.5 percentiles) INSL3 serum levels were as follows:

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.